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Vanilloid Receptor-1 (VR1) is Widely Expressed on Various
Epithelial and Mesenchymal Cell Types of Human Skin
To the Editor:
A subset of sensory neurons can be defined by their
susceptibility to capsaicin and related vanilloids (Szallasi
and Blumberg, 1999). The molecular target of these agents
is the vanilloid receptor-1 (VR1), which functions as a
calcium-permeable non-specific cation channel (Caterina
et al, 1997). This receptor can also be activated by heat and
acidosis, and by endogenous ‘‘endovanilloids’’ such as
arachidonic acid derivatives and eicosanoids (Di Marzo
et al, 2002). Therefore, VR1 was suggested as a key
integrator molecule of various nociceptive stimuli.
In addition to its presence on sensory neurons, functional
VR1s have also been identified on various non-neuronal cell
types in vitro. We have previously shown that activation of
VR1 in mast cells (Bı´ro´ et al, 1998b) and glial cells (Bı´ro´ et al,
1998a), similar to findings by others on bronchial (Veronesi
et al, 1999) and uroepithelial cells (Birder et al, 2001),
resulted in the onset of a variety of cellular processes such
as changes in proliferation, apoptosis, differentiation, and
cytokine release.
Very recently, a functional VR1 was also identified on
human epidermal keratinocytes (NHEK, Denda et al, 2001;
Inoue et al, 2002; Southall et al, 2003). It is not clear,
however, whether VR1 is also expressed in normal human
skin in addition to sensory neurons and keratinocytes.
Therefore, in this study, our goal was to characterize VR1
immunoreactivity on epithelial and mesenchymal cells of
normal human skin in situ.
Normal skin samples (n¼ 7; trunk, back), obtained during
plastic surgery, were used as either frozen or formaldehyde-
fixed sections embedded in paraffin (3–5 mm thickness in
both cases). To detect VR1, a streptavidin–biotin-complex
(SABC) three-step immunohistochemical technique (DAKO,
Hamburg, Germany) was employed. Inhibition of endogen-
ous peroxidase activity was performed using 0.5% H2O2 in
100% methanol. Non-specific binding of the antibodies was
blocked by 2% bovine serum albumin (BSA, Sigma, St
Louis, Missouri) in phosphate-buffered saline (pH 7.6).
Sections were first incubated with an anti-VR1 goat primary
antibody against the N-terminus of VR1 (1:20 dilution, Santa
Cruz, Santa Cruz, California), then with a biotin-coupled anti-
goat secondary antibody (1:500, DAKO), and, finally, with
streptavidin conjugated with horseradish peroxidase (1:400,
DAKO). To reveal the peroxidase activity, DAB (Vector,
Burlingame, California) or VIP SK-4600 (Vector) was
employed as chromogenes. Tissue samples were finally
slightly counterstained with hematoxylin Gill I (Surgipath
Europe, Peterborough, UK) and mounted with Aquatex
(Merck, Vienna, Austria).
In control experiments, the specificity of VR1 stain-
ing was assessed by (1) omitting the primary antibody or
by incubating the sections with the VR1 antibody pre-
absorbed with a synthetic blocking peptide (Santa Cruz)
(Fig 1G); (2) using another antibody against the C-terminus
of VR1 (Santa Cruz), which resulted in an identical staining
pattern (data not shown); and (3) performing VR1 immu-
nostaining on frozen skin sections from wild-type C57BL/6J
and VR1 knock-out (VR1/KO) B6.129S4-Trpv1 mice (The
Jackson Laboratory, Bar Harbor, Maine) (Fig 1J, K). In this
latter case, a fluorescein-isothiocyanate (FITC)-conjugated
secondary antibody was used for visualization. Frozen
sections of rat spinal cord were used as positive tissue
controls (Fig 1H, I).
For double immunohistochemistry, frozen skin sections
were first labeled to detect VR1 as described above and
then were again blocked using 2% BSA. To detect mast
cells or dendritic cells, sections were incubated with either a
monoclonal mouse anti-human mast cell tryptase antibody
(1:50, DAKO) or with a monoclonal mouse anti-CD1a (a
dendritic cell-specific marker) antibody (1:20, Novocastra,
Newcastle upon Tyne, UK), then with biotin-conjugated anti-
mouse secondary antibody (1:500, DAKO), and, finally, with
alkaline phosphatase-conjugated streptavidine (1:50 dilu-
tion, DAKO). Endogenous alkaline phosphatase activity was
blocked using Levamisole (Sigma), and Fast blue BB
(Sigma) was applied as a chromogene.
To detect VR1 mRNA expression, skin homogenates
were pulverized in liquid N2. Total RNA was then isolated
using TRIzol (Invitrogen, Paisley, UK) and was reverse
transcribed strictly following the procedure described
before (Southall et al, 2003). PCR amplification was
performed using human VR1-specific primers: sense, 50-
ctcctacaacagcctgtac-30; antisense, 50-aaggcccagtgttgacagtg-
30 (RT-PCR).
To detect VR1 protein expression, skin homogenates
(60–80 mg protein) were subjected to SDS-PAGE as
described before (La´za´r et al, 2003). VR1 expression was
determined by immunoblotting using the above goat anti-
VR1 antibody, a horseradish peroxidase-conjugate rabbit
anti-goat secondary antibody (BioRad, Wien, Austria), and
enhanced chemiluminescence (Amersham, Little Chalfont,
England). For the RT-PCR and western blot analyses,
cultured NHEK and HaCaT keratinocytes were used as
VR1-expressing positive controls (Denda et al, 2001;
Southall et al, 2003). The study was approved by the
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Institutional Research Ethics Committee and adhered to
Declaration of Helsinki guidelines.
Since we are currently investigating in detail VR1 expres-
sion and function in human hair biology in a separate study,
hair follicle VR1 immunoreactivity patters were ignored in
this manuscript (Bodo´ et al, manuscript in preparation).
Using immunolabeling on paraffin-embedded human
skin samples, specific VR1 immunoreactivity (VR1-ir) was
identified on several cell types of human skin (Table I). The
specificity of VR1-ir was approved by using various positive
and negative controls (Fig 1G–I), including skin sections of
VR1/KO mice in which there was a complete lack of VR1-ir
(Fig 1J, K). With respect to the epidermis, confirming pre-
vious data (Denda et al, 2001), VR1 was expressed in the
epidermal keratinocytes. The VR1-ir pattern, however, was
inhomogeneous; i.e., whereas a rather strong cytoplasmic
and nuclear VR1-ir was detected in the basal and spinous
layers, much weaker signals were found in the suprabasal
layers (Fig 1A). Of great novelty, VR1 was also expressed
in CD1a-positive epidermal Langerhans cells (Fig 1B).
Epidermal melanocytes, instead, were negative for VR1
(data not shown).
In addition to sensory nerve fibers (which also served
as positive controls, Fig 1C), we demonstrated VR1-ir, for
the first time, on various cells populations of the dermis.
A strong VR1-ir was observed on sebocytes (Fig 1D) and
sweat gland epithelium (Fig 1E), on endothelial and smooth
muscle cells of skin blood vessels (Fig 1C–F), on smooth
muscles (Fig 1D), and on tryptase-positive dermal mast
cells (Fig 1F). Connective tissue fibroblasts showed no VR1-
ir (Fig 1C). There was no difference in the VR1 expression
pattern of skin samples of different patients or of different
body sites (data not shown). Finally, the presence of VR1 in
human skin, both at the mRNA and protein levels, was also
demonstrated using Western blotting (Fig 1L) and RT-PCR
(Fig 1M).
The complex functional roles of VR1 signaling in human
skin biology and pathology now await dissection and
clarification. One straightforward possibility is that VR1,
functioning as a calcium-permeable channel (Caterina et al,
1997; Szallasi and Blumberg, 1999), upon activation, leads
to an increase in intracellular calcium concentration
([Ca2þ ]i) and hence may initiate calcium-mediated pro-
cesses. Such calcium-coupled mechanisms were de-
scribed for urinary epithelial cells (nitric oxide release)
(Birder et al, 2001), glial cells (proliferation, differentiation,
apoptosis) (Bı´ro´ et al, 1998a), and mast cells and epidermal
keratinocytes (pro-inflammatory mediator release) (Bı´ro´ et al,
1998b; Southall et al, 2003). In addition, since most skin cell
functions are strongly affected by [Ca2þ ]i (Hennings
et al, 1980; Bikle and Pillai, 1993; Vicanova et al, 1998),
VR1 may possess a significant role, e.g., in the regulation of
keratinocyte differentiation and proliferation. This is sup-
ported by our demonstration that the expression of VR1
Figure1
VR1 immunoreactivity and protein and mRNA expression on
human skin. (A) Immunoreactivity for VR1 (VR1-ir) on epidermal
keratinocytes. Note the stronger staining observed on basal (BK) than
on suprabasal (SBK) keratinocytes (E, epidermis). (B) Co-localization of
VR1 (brown) and CD1a (blue) on Langerhans cells (arrow) of the
epidermis (E), as revealed by double immunolabeling. (C) VR1-ir on
nerve fibers (N) and endothelium and smooth muscle cells of dermal
blood vessels (V). Note the lack of VR-ir on dermal fibroblasts (F,
arrows). (D) VR1-ir on sebocytes (SC), endothelial and smooth muscle
cells of blood vessels (V), and on smooth muscle of dermis (SM). (E)
VR1 expression on sweat gland epithelium (SW, arrows) (C, capillary).
(F) Co-localization of VR1 (brown) and mast cell-specific tryptase (blue)
on dermal mast cells (arrows) (E, epidermis; C, capillary). (G) Negative
control. Specificity of staining was assessed by incubating skin
sections with the VR1 antibody pre-absorbed with a synthetic blocking
peptide. (H) Positive control. VR1-ir (arrows), as observed on the dorsal
horn (DH) of rat spinal cord. (I) Negative control. Lack of VR1-ir (arrows)
on dorsal horn (DH) of rat spinal cord when stained with the VR1
antibody pre-absorbed with a synthetic blocking peptide. (J, K) VR1-ir
on skin of wild type C57BL/6J (J) and VR1/KO (K) mice (an FITC-
conjugated secondary antibody was used for visualization). E,
epidermis; SC, sebocytes. (A, C, D, E, G). Paraffin-embedded sections.
(B, F, H, I–K) Frozen sections. In most cases, DAB was used to develop
VR1-ir, except for C, where VIP SK-4600 was applied as a chromogene;
and C, where VIP SK-4600 was applied as a chromogene. Original
magnifications, A–F:  400; G:  40;  H–K:  100. (L) Western
blot analysis of VR1 protein expression (approximately 90 kDa) in
human skin homogenates and in NHEK and HaCaT keratinocytes. (M)
RT-PCR analysis of VR1 mRNA expression (predicted size of
approximately 680 base pairs, bp) in human skin homogenates and
in NHEK and HaCaT keratinocytes.
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among epidermal keratinocytes appeared to be linked to
their distinct differentiation status (Fig 1A). In fact, activation
of VR1 by capsaicin in cultured HaCaT keratinocytes results
in a concentration-dependent inhibition of proliferation (Bı´ro´
et al, unpublished observations).
Our findings may possess even therapeutic significance.
The VR1 agonist capsaicin was previously described to act
exclusively indirectly on non-neuronal cells of skin via the
release of various neuropeptides from sensory neurons
(Bı´ro´ et al, 1998b; Szallasi and Blumberg, 1999; Townley
et al, 2002). This study, however, clearly argues for that
activators of VR1 signaling can directly target cutaneous
structures other than sensory neurons. Therefore, the
‘‘dual’’ activation of VR1 by exogenous capsaicin or
‘‘endovanilloids’’ on neuronal and non-neuronal cell types
of the skin likely results in the simultaneous release of
neuropeptides from sensory axons and of other mediators
(e.g., histamine, pro-inflammatory cytokines) from keratino-
cytes, mast cells, or endothelial cells. This could activate
a complex, multi-directional signaling cascade augmenting
the action of the VR1 agonist. No wonder, therefore, that
capsaicin application was found to be most effective in the
treatment of chiefly histamine-dependent and/or neuro-
genic pruritic skin disorders (Greaves and Wall, 1996; Bı´ro´
et al, 1997; Sta¨nder et al, 2001, 2003).
In conclusion, in this study, we presented evidence that
VR1-ir is expressed not only on epidermal keratinocytes
of normal human skin (Denda et al, 2001) but also by
neuroectodermal and mesenchymal cell types such as
Langerhans cells, sebocytes, sweat gland epithelium,
endothelial and smooth muscle cells of skin blood vessels,
and mast cells. This widespread, but certainly not ubi-
quitous, VR1 protein expression pattern suggests multiple,
previously unappreciated additional functions for VR1-
mediated signaling, well beyond nociception.
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E, neuroectodermal; M, mesenchymal.
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